DE69620898D1 - Interaktive molekulare konjugate - Google Patents

Interaktive molekulare konjugate

Info

Publication number
DE69620898D1
DE69620898D1 DE69620898T DE69620898T DE69620898D1 DE 69620898 D1 DE69620898 D1 DE 69620898D1 DE 69620898 T DE69620898 T DE 69620898T DE 69620898 T DE69620898 T DE 69620898T DE 69620898 D1 DE69620898 D1 DE 69620898D1
Authority
DE
Germany
Prior art keywords
binding
binding site
site
stimuli
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69620898T
Other languages
English (en)
Other versions
DE69620898T2 (de
Inventor
S Hoffman
S Stayton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of DE69620898D1 publication Critical patent/DE69620898D1/de
Application granted granted Critical
Publication of DE69620898T2 publication Critical patent/DE69620898T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
DE69620898T 1995-09-01 1996-08-30 Interaktive molekulare konjugate Expired - Fee Related DE69620898T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US314895P 1995-09-01 1995-09-01
PCT/US1996/013874 WO1997009068A2 (en) 1995-09-01 1996-08-30 Interactive molecular conjugates

Publications (2)

Publication Number Publication Date
DE69620898D1 true DE69620898D1 (de) 2002-05-29
DE69620898T2 DE69620898T2 (de) 2002-11-07

Family

ID=21704411

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69620898T Expired - Fee Related DE69620898T2 (de) 1995-09-01 1996-08-30 Interaktive molekulare konjugate

Country Status (8)

Country Link
US (1) US5998588A (de)
EP (1) EP0851768B1 (de)
JP (1) JP2000500733A (de)
AT (1) ATE216594T1 (de)
AU (1) AU716154B2 (de)
CA (1) CA2230557A1 (de)
DE (1) DE69620898T2 (de)
WO (1) WO1997009068A2 (de)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
CA2291622C (en) 1997-06-06 2007-09-04 Anna Gutowska Reversible geling co-polymer and method of making
AU2002301047B2 (en) * 1997-06-20 2005-11-10 Ciphergen Biosystems, Inc. Retentate Chromatography And Protein Chip Arrays With Applications In Biology And Medicine
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
EP0922715B8 (de) * 1997-12-09 2008-05-21 National Institute of Advanced Industrial Science and Technology Via Keto-Enol-Tautomerie auf Stimuli reagierendes Polymer
GB9726888D0 (en) * 1997-12-20 1998-02-18 Eev Ltd Detection
JP2002500201A (ja) * 1998-01-05 2002-01-08 ユニバーシティ オブ ワシントン 膜破壊剤を使用する増強された輸送
US6296831B1 (en) 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
EP1006362A1 (de) * 1998-12-02 2000-06-07 Michael Dr. Cahill Methode und Apparat für die Abtrennung von Komponenten aus einem biologischen Material
WO2000056774A1 (en) * 1999-03-19 2000-09-28 Duke University Methods of using bioelastomers
GB9923146D0 (en) * 1999-09-30 1999-12-01 Imperial College Detector array
US6258275B1 (en) * 1999-10-01 2001-07-10 Ecole Polytechnique Federale De Lausanne Affinity macroligands
JP2003514650A (ja) 1999-11-15 2003-04-22 バイオキュア・インコーポレーテッド 応答性ポリマー性中空粒子
WO2001051092A2 (en) 2000-01-07 2001-07-19 University Of Washington Enhanced transport of agents using membrane disruptive agents
US7163712B2 (en) 2000-03-03 2007-01-16 Duke University Microstamping activated polymer surfaces
US6444254B1 (en) 2000-03-03 2002-09-03 Duke University Microstamping activated polymer surfaces
EP1281436A4 (de) * 2000-04-05 2003-07-09 Japan Chemical Innovation Inst Neue substanz zur verwendung in trennprozessen und zugehörige trennverfahren
US6660247B1 (en) * 2000-06-23 2003-12-09 Battelle Memorial Institute Multiple stimulus reversible hydrogels
AU2001270231A1 (en) * 2000-06-28 2002-01-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Localized delivery to a target surface
EP1227321A1 (de) * 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Funktionelle Reinigung von Antigen spezifischen T Lymphozyten durch Peptide-MHC Multimer Färbung
JP4797143B2 (ja) * 2001-01-31 2011-10-19 独立行政法人産業技術総合研究所 触媒反応制御方法
WO2002061406A1 (en) 2001-02-01 2002-08-08 Sigma-Aldrich Co. Improved affinity matrices with enhanced visibility for molecular pull-down and immunoprecipitation applications
CN1268921C (zh) * 2001-07-31 2006-08-09 三菱丽阳株式会社 其内壁引入了梳形聚合物的中空纤维、填充有凝胶的中空纤维以及纤维束的薄切片
US7456025B2 (en) * 2001-08-28 2008-11-25 Porex Corporation Sintered polymer membrane for analyte detection device
US20030108972A1 (en) * 2001-12-06 2003-06-12 Zweig Stephen Eliot Tethered receptor-ligand reagent and assay
US20040241173A1 (en) * 2002-02-14 2004-12-02 William Marsh Rice University Fullerene (C60) vancomycin conjugates as improved antibiotics
DE10224352A1 (de) * 2002-06-01 2003-12-11 Mueller Schulte Detlef Thermosensitive Polymerträger mit veränderbarer physikalischer Struktur für die biochemische Analytik, Diagnostik und Therapie
AU2003254092A1 (en) * 2002-07-19 2004-02-09 Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University Localized delivery system for phenstatin using n-isopropylacrylamide
WO2004011600A2 (en) * 2002-07-29 2004-02-05 Mt Technologies, Inc. Biomimetic membranes
CN100377766C (zh) * 2002-07-29 2008-04-02 Mt技术股份有限公司 仿生膜
US20040062882A1 (en) * 2002-09-30 2004-04-01 Andrea Liebmann-Vinson Cell adhesion resisting surfaces
AU2003290598A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
CA2505090A1 (en) * 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Conjugated oligomeric compounds and their use in gene modulation
AU2002953073A0 (en) * 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
TWI354021B (en) * 2002-12-23 2011-12-11 Alcon Inc Compositions and methods for inhibiting protein on
US7083948B1 (en) 2002-12-24 2006-08-01 Immunex Corporation Polypeptide purification reagents and methods for their use
TWI257928B (en) * 2002-12-27 2006-07-11 Ind Tech Res Inst Method for the separation of polysaccharides
EP1631375B1 (de) 2003-01-17 2011-11-02 Cornell Research Foundation, Inc. Injizierbare hydrogel-microsphären aus wässrigem zwei-phasen-system
US7695752B2 (en) 2003-01-24 2010-04-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target activated microtransfer
AU2003256803B2 (en) * 2003-01-24 2009-09-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target activated microtransfer
WO2004072258A2 (en) * 2003-02-11 2004-08-26 University Of Washington Stimuli-responsive polymer conjugates and related methods
SE0300791D0 (sv) * 2003-03-20 2003-03-20 Amersham Biosciences Ab Use of ph-responsive polymers
WO2005039641A2 (en) * 2003-10-15 2005-05-06 The Regents Of The University Of California Biomacromolecule polymer conjugates
DE10350248A1 (de) * 2003-10-28 2005-06-16 Magnamedics Gmbh Thermosensitive, biokompatible Polymerträger mit veränderbarer physikalischer Struktur für die Therapie, Diagnostik und Analytik
US20050096446A1 (en) * 2003-10-29 2005-05-05 Council Of Scientific And Industrial Tri-block copolymers and a process for the preparation of the same
US7514399B2 (en) 2003-11-05 2009-04-07 Photobiomed Corporation Bonding tissues and cross-linking proteins with naphthalimide compounds
US7390628B2 (en) * 2003-12-23 2008-06-24 University Of Florida Research Foundation, Inc. Microparticle-based diagnostic methods
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
GB0412631D0 (en) * 2004-06-07 2004-07-07 Cambridge Applied Polymers Ltd Polymer release system
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
WO2006044785A1 (en) * 2004-10-18 2006-04-27 E.I. Dupont De Nemours And Company Process for making antimicrobial polymer articles
JP2006158305A (ja) * 2004-12-08 2006-06-22 National Institute Of Advanced Industrial & Technology 細胞分離用吸着材、細胞分離用吸着材モジュール及び細胞分離方法
EP1850858A2 (de) * 2005-02-10 2007-11-07 Emory University Polyethylenoxid-polymere mit entzündungshemmenden glycodendronen
US8157807B2 (en) 2005-06-02 2012-04-17 The Invention Science Fund I, Llc Skin treatment including patterned light
JP2006312117A (ja) * 2005-05-06 2006-11-16 Canon Inc 生理活性物質の分離用材料及びその製造方法
GB0515625D0 (en) * 2005-07-29 2005-09-07 Univ Manchester Hydrogel particle
JP2007071832A (ja) * 2005-09-09 2007-03-22 Shiseido Co Ltd 修飾金粒子
US7957466B2 (en) * 2005-09-16 2011-06-07 Sony Corporation Adaptive area of influence filter for moving object boundaries
US8114843B2 (en) 2005-11-18 2012-02-14 The Regents Of The University Of California Photoreactive regulator of protein function and methods of use thereof
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US7709227B2 (en) * 2006-01-04 2010-05-04 Phasebio Pharmaceuticals, Inc. Multimeric ELP fusion constructs
US7718193B2 (en) * 2006-03-16 2010-05-18 University Of Washington Temperature- and pH-responsive polymer compositions
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8815518B2 (en) 2006-06-30 2014-08-26 Jnc Corporation Kit for detection/quantification of analyte, and method for detection/quantification of analyte
US8569464B2 (en) * 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
WO2008079302A2 (en) * 2006-12-21 2008-07-03 Millipore Corporation Purification of proteins
US8362217B2 (en) * 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
US7981688B2 (en) 2007-03-08 2011-07-19 University Of Washington Stimuli-responsive magnetic nanoparticles and related methods
US20100151465A1 (en) 2008-03-27 2010-06-17 Jingyue Ju Selective Capture and Release of Analytes
ES2613029T3 (es) 2007-11-12 2017-05-22 Chreto Aps Polipéptidos de afinidad doble para purificación
JP5193228B2 (ja) * 2007-12-28 2013-05-08 オーソ・クリニカル・ダイアグノスティックス株式会社 検出対象の検出方法及び定量方法
CA2710586C (en) * 2007-12-28 2014-02-18 Chisso Corporation Detection method and determination method for detection target
US8999702B2 (en) * 2008-06-11 2015-04-07 Emd Millipore Corporation Stirred tank bioreactor
CN102131516B (zh) 2008-06-27 2016-03-16 杜克大学 包含弹性蛋白样肽的治疗剂
DK2344269T3 (da) * 2008-10-07 2019-12-02 Applied Biomimetic As Biomimetisk membran dannet af tråde med vedhæftede vesikler
US20100150952A1 (en) * 2008-11-07 2010-06-17 University Of Washington pH-RESPONSIVE POLYMER CARRIER COMPOSITIONS FOR CYTOSOLIC PROTEIN DELIVERY
JP2012511929A (ja) 2008-12-16 2012-05-31 イー・エム・デイー・ミリポア・コーポレイシヨン 攪拌タンク反応器及び方法
US8827971B2 (en) 2011-04-29 2014-09-09 Seventh Sense Biosystems, Inc. Delivering and/or receiving fluids
US20110288389A9 (en) 2009-03-02 2011-11-24 Seventh Sense Biosystems, Inc. Oxygen sensor
WO2010101620A2 (en) 2009-03-02 2010-09-10 Seventh Sense Biosystems, Inc. Systems and methods for creating and using suction blisters or other pooled regions of fluid within the skin
WO2012018486A2 (en) 2010-07-26 2012-02-09 Seventh Sense Biosystems, Inc. Rapid delivery and/or receiving of fluids
US9090663B2 (en) * 2009-04-21 2015-07-28 The Trustees Of Columbia University In The City Of New York Systems and methods for the capture and separation of microparticles
EP2437059A4 (de) * 2009-05-29 2013-02-27 Jnc Corp Detektionsverfahren und quantifizierungsverfahren eines detektionsziels
US8426214B2 (en) * 2009-06-12 2013-04-23 University Of Washington System and method for magnetically concentrating and detecting biomarkers
PL2464370T3 (pl) 2009-08-14 2017-08-31 Phasebio Pharmaceuticals, Inc. Modyfikowane wazoaktywne peptydy jelitowe
US20110117668A1 (en) * 2009-11-09 2011-05-19 University Of Washington Through Its Center For Commercialization Self-powered smart diagnostic devices
US9080933B2 (en) 2009-11-09 2015-07-14 University Of Washington Through Its Center For Commercialization Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates
CN106913902A (zh) 2009-11-09 2017-07-04 聚光灯技术合伙有限责任公司 多糖基水凝胶
US8795727B2 (en) 2009-11-09 2014-08-05 Spotlight Technology Partners Llc Fragmented hydrogels
WO2011094573A1 (en) 2010-01-28 2011-08-04 Seventh Sense Biosystems, Inc. Monitoring or feedback systems and methods
KR101551295B1 (ko) * 2010-05-17 2015-09-08 이엠디 밀리포어 코포레이션 생체분자 정제용 자극 반응성 중합체
WO2011163347A2 (en) 2010-06-23 2011-12-29 Seventh Sense Biosystems, Inc. Sampling devices and methods involving relatively little pain
JP2013538069A (ja) 2010-07-16 2013-10-10 セブンス センス バイオシステムズ，インコーポレーテッド 流体移動デバイスのための低圧環境
WO2012021801A2 (en) 2010-08-13 2012-02-16 Seventh Sense Biosystems, Inc. Systems and techniques for monitoring subjects
US8808202B2 (en) 2010-11-09 2014-08-19 Seventh Sense Biosystems, Inc. Systems and interfaces for blood sampling
US8298298B1 (en) 2010-12-22 2012-10-30 Empire Development Technology LLC Dyes with changeable solubilities, and methods for their use
US8246698B2 (en) 2010-12-22 2012-08-21 Empire Technology Development Llc Dyes with changeable solubilities, and methods for their use
WO2012149155A1 (en) 2011-04-29 2012-11-01 Seventh Sense Biosystems, Inc. Systems and methods for collecting fluid from a subject
CA2833175A1 (en) 2011-04-29 2012-11-01 Seventh Sense Biosystems, Inc. Devices and methods for collection and/or manipulation of blood spots or other bodily fluids
US20130158468A1 (en) 2011-12-19 2013-06-20 Seventh Sense Biosystems, Inc. Delivering and/or receiving material with respect to a subject surface
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
WO2013019714A1 (en) 2011-07-29 2013-02-07 The Trustees Of Columbia University In The City Of New York Mems affinity sensor for continuous monitoring of analytes
TWI425096B (zh) * 2012-02-10 2014-02-01 Nat Applied Res Laboratories 利用生物分子改質基板表面的方法
CN104487457B (zh) 2012-05-30 2018-01-26 中外制药株式会社 靶组织特异性抗原结合分子
WO2014121802A1 (en) * 2013-02-07 2014-08-14 Zaghloul Mohammad Hosam Eldeen Innovative nano-elisa single test for the detection of hcv, hiv antibodies and hbsag
US9539338B2 (en) 2013-04-22 2017-01-10 Carnegie Mellon University Polymer-based protein engineering methods to rationally tune enzyme activity, pH-dependence and stability
US10359419B2 (en) * 2013-10-02 2019-07-23 General Electric Company Methods for detection of target using affinity binding
US20150093839A1 (en) * 2013-10-02 2015-04-02 General Electric Company Methods and systems for detection of target and applications thereof
TW202043467A (zh) * 2013-12-04 2020-12-01 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
WO2015172046A1 (en) 2014-05-08 2015-11-12 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
WO2016022696A1 (en) 2014-08-05 2016-02-11 The Trustees Of Columbia University In The City Of New York Method of isolating aptamers for minimal residual disease detection
WO2016130518A2 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
JP6778380B2 (ja) 2016-08-23 2020-11-04 昭和電工マテリアルズ株式会社 吸着材
GB201615989D0 (en) 2016-09-20 2016-11-02 Imp Innovations Ltd Drug Delivery
DE102016119102A1 (de) * 2016-10-07 2018-04-12 Forschungszentrum Jülich GmbH Translokation von synthetischen Polymeren durch Lipidmembrane
EP3568159A4 (de) 2017-01-11 2020-08-05 Bristol-Myers Squibb Company Psgl-1-antagonisten und verwendung davon
JP7211961B2 (ja) 2017-03-14 2023-01-24 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体
WO2018185503A1 (en) 2017-04-07 2018-10-11 The University Of Birmingham Stimuli-responsive surfaces
US10450345B2 (en) * 2017-06-09 2019-10-22 General Electric Company Method of isolation of polypeptide-aptamer-polymer conjugates
US11472894B2 (en) 2018-07-23 2022-10-18 Carnegie Mellon University Enzyme-assisted ATRP procedures
JP2020020719A (ja) * 2018-08-02 2020-02-06 キヤノンメディカルシステムズ株式会社 分析方法、試薬キット及び分析装置
WO2021078813A1 (en) * 2019-10-21 2021-04-29 Mip Diagnostics Limited Thermally responsive conjugates

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843010A (en) * 1983-11-10 1989-06-27 Genetic Systems Corporation Polymerization-induced separation immunoassays
US4752638A (en) * 1983-11-10 1988-06-21 Genetic Systems Corporation Synthesis and use of polymers containing integral binding-pair members
US4609707A (en) * 1983-11-10 1986-09-02 Genetic Systems Corporation Synthesis of polymers containing integral antibodies
GB8423228D0 (en) * 1984-09-14 1984-10-17 Unilever Plc Specific binding materials
DE3583940D1 (de) * 1984-10-02 1991-10-02 Harry M Meade Herstellung von streptavidinaehnlichen polypeptiden.
US4780409A (en) * 1985-05-02 1988-10-25 Genetic Systems Corporation Thermally induced phase separation immunoassay
JPS61265090A (ja) * 1985-05-17 1986-11-22 Tanabe Seiyaku Co Ltd 可逆溶解性固定化酵素
US4839293A (en) * 1986-02-24 1989-06-13 The Trustees Of Columbia University In The City Of New York DNA encoding streptavidin, streptavidin produced therefrom, fused polypeptides which include amino acid sequences present in streptavidin and uses thereof
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4971905A (en) * 1987-08-11 1990-11-20 Pacific Northwest Research Foundation Diagnosis of cancerous or precancerous conditions in human secretory epithelia by enzyme activity of β-1-3N-acetylglucosaminyltransferase
US5135876A (en) * 1987-09-24 1992-08-04 University Of Utah Method and apparatus for the regulation of complex binding
US5013669A (en) * 1988-06-01 1991-05-07 Smithkline Diagnostics, Inc. Mass producible biologically active solid phase devices
US5112770A (en) * 1988-06-08 1992-05-12 North Carolina State University Precipitation of multivalent antiligands with affinity surfactants
JPH0383914A (ja) * 1989-08-18 1991-04-09 W R Grace & Co ドラッグキャリアー
EP0469681B1 (de) * 1990-08-03 1994-10-12 Koninklijke Philips Electronics N.V. Optischer Verstärker
EP0470681A3 (en) * 1990-08-08 1992-04-22 W.R. Grace & Co.-Conn. Cell clusters or sheets comprising a plurality of cell species and preparations thereof
US5226902A (en) * 1991-07-30 1993-07-13 University Of Utah Pulsatile drug delivery device using stimuli sensitive hydrogel
US5417983A (en) * 1992-02-19 1995-05-23 Sagami Chemical Research Center Drug release controlling material responsive to changes in temperature
US5753261A (en) * 1993-02-12 1998-05-19 Access Pharmaceuticals, Inc. Lipid-coated condensed-phase microparticle composition

Also Published As

Publication number Publication date
US5998588A (en) 1999-12-07
AU716154B2 (en) 2000-02-17
JP2000500733A (ja) 2000-01-25
ATE216594T1 (de) 2002-05-15
WO1997009068A2 (en) 1997-03-13
WO1997009068A3 (en) 1997-08-28
CA2230557A1 (en) 1997-03-13
DE69620898T2 (de) 2002-11-07
EP0851768A2 (de) 1998-07-08
AU7011096A (en) 1997-03-27
EP0851768B1 (de) 2002-04-24

Similar Documents

Publication Publication Date Title
ATE216594T1 (de) Interaktive molekulare konjugate
ATE384792T1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
DE69327229T2 (de) Multivalente einkettige Antikörper
DK1027439T3 (da) Multivalente antigenbindende proteiner
DE69409788D1 (de) Methoden fuer analyse/ trennung
CY1109876T1 (el) Μεθοδοι για εκλεκτικη στοχευση
DE69332858D1 (de) EINGESCHRÄNKTES MULTIFUNKTIONELLES REAGENs ZUR OBERFLÄCHENMODIFIKATION
ATE474854T1 (de) Rsv neutralisierende antikörper mit sehr hohen affinität
ATE395599T1 (de) Gegenstand mit einer ungeladenen, funktionalisierten hydrogeloberfläche
ATE461211T1 (de) Liganden mit antikörperbindender affinität
ATE270429T1 (de) Verfahren und vorrichtung zur erkennung von molekül-bindungsreaktionen
DE69937450D1 (de) Methoden zur gestaltung von proteingebundenen lipidischen mikropartikeln und verbindungen damit
DE69714654D1 (de) Verwendung von einem Metalloporphyrinkonjugat für den Nachweis biologischer Verbindungen
DE69624920T2 (de) Testreagentien und Testvorrichtungen
DE69114394T2 (de) Analytisches Element mit biologisch aktivem Reagens und Verfahren zur Verwendung des Reagens.
DE69430523T2 (de) Herstellung von photoprotein konjugaten und verfahren zu ihrer verwendung
ATE319735T1 (de) Aufreinigung von substanzen aus einer biologischen probe
Shreder Synthetic haptens as probes of antibody response and immunorecognition
DE69619257D1 (de) Die konjugation von liganden an immobilisierte proteine in einem organischen lösungsmittel
DE69922245D1 (de) Biologisch wirksame konjugate mit einem reporterrest und verfahren zu dessen nachweis
WO2001050127A8 (en) Screening using biological target molecules with metal-ion binding sites
DE69909312D1 (de) Methoden zur identifizierung von "hot-spot" resten bindender proteine und kleine verbindungen die an diese binden
ATE89925T1 (de) Immunoadsorbens mit geringer freisetzungsrate und verfahren zu seiner herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee